In:
PLOS ONE, Public Library of Science (PLoS), Vol. 17, No. 4 ( 2022-4-21), p. e0266738-
Abstract:
Gallbladder cancer (GBC) is the most common biliary tract malignancy with a dismal prognosis. The development of new drugs may help to improve prognosis. This study found that fangchinoline, a bisbenzylisoquinoline alkaloids, inhibited the proliferation and clone formation of GBC cells in a dose-dependent manner. Moreover, Hoechst staining, TUNEL assays, and flow cytometry demonstrated that fangchinoline effectively induced apoptosis in GBC cells. Further studies found that an anti-apoptotic pathway, the PI3K/Akt/XIAP axis, was significantly inhibited in GBC cells after treating with fangchinoline. Finally, we confirmed that fangchinoline restrained xenograft tumor growth in vivo. Our findings indicate that fangchinoline can be considered a potential drug for GBC treatment.
Type of Medium:
Online Resource
ISSN:
1932-6203
DOI:
10.1371/journal.pone.0266738
DOI:
10.1371/journal.pone.0266738.g001
DOI:
10.1371/journal.pone.0266738.g002
DOI:
10.1371/journal.pone.0266738.g003
DOI:
10.1371/journal.pone.0266738.g004
DOI:
10.1371/journal.pone.0266738.t001
DOI:
10.1371/journal.pone.0266738.s001
DOI:
10.1371/journal.pone.0266738.s002
DOI:
10.1371/journal.pone.0266738.r001
DOI:
10.1371/journal.pone.0266738.r002
DOI:
10.1371/journal.pone.0266738.r003
DOI:
10.1371/journal.pone.0266738.r004
Language:
English
Publisher:
Public Library of Science (PLoS)
Publication Date:
2022
detail.hit.zdb_id:
2267670-3
Permalink